Answers are grounded in this paper and cite their sources.
Infectious diseases continue to pose a global health challenge, intensified by antimicrobial resistance and limitations of pharmaceutical countermeasures. Nanotechnology offers a promising front against these barriers using intelligent, multifunctional systems. This review explores the convergence of Artificial Intelligence (AI), CRISPR gene editing, bacteriophage therapy, and immune modulation within the framework of second-generation nanoparticle therapeutics. AI-guided modelling enables predictive optimization of nanoparticle design on the basis of size, charge, and surface proteins, targeting specific pathogens and providing enhanced stability. Consequently, nanoparticles serve as precision nanocarriers and protective delivery vehicles for the CRISPR-Cas system, shielding nucleic acid cargo from enzymatic degradation and enabling targeted intracellular delivery via pH-responsive endosomal escape mechanisms. The nanoparticles not only provide protection but also enable tissue-targeting and infection-site-specific delivery of the CRISPR-Cas system, facilitating precise genome editing to reverse resistance in specific pathogens such as HIV and Mycobacterium tuberculosis. Phage nanoparticle hybrids further expand antimicrobial potency by enhancing phage stability, delivery, and host range. Moreover, engineered nanoparticles modulate the immune system via immunosuppressive and immunostimulant strategies for reducing hyperinflammation and enhancing pathogen clearance, respectively. Despite such encouraging laboratory outcomes, the clinical translation of AI-integrated nanoparticle platforms still faces a number of obstacles. Large-scale manufacturing, scalability, and reproducibility pose a significant challenge. Regulatory approvals for such multi-modal nano-drugs seem to get bogged down due to vague and scarce exemplary proofs. Furthermore, safety and efficacy apprehensions, unpredictable and complex host-phage interactions, cost-effectiveness, and equitable access remain a subject matter of concern. Conclusively, the convergence of advanced nanotechnology, artificial intelligence, and synthetic biology marks the dawn of a transformative era in infectious disease therapeutics where treatment is not only intelligent and adaptive but also ethically and globally inclusive. Clinical trial registration Not applicable.
No takes yet. Share an insight, caveat, or question.
Mehmood et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: